Proteon Therapeutics Inc  

(Public, NASDAQ:PRTO)   Watch this stock  
Find more results for PRTO
2.30
0.00 (0.00%)
Feb 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.20 - 2.45
52 week 1.10 - 2.85
Open 2.35
Vol / Avg. 22,023.00/85,685.00
Mkt cap 40.52M
P/E     -
Div/yield     -
EPS -2.22
Shares 17.62M
Beta 1.78
Inst. own 75%
Mar 14, 2018
Q4 2017 Proteon Therapeutics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -120.11% -51.37%
Return on average equity -322.28% -56.02%
Employees 19 -
CDP Score - -

Address

200 West St
WALTHAM, MA 02451-1121
United States - Map
+1-781-8900102 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company's product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.

Officers and directors

Paul J. Hastings Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Timothy P. Noyes President, CEO, Director
Age: 55
Bio & Compensation  - Reuters
George A. Eldridge Chief Financial Officer, Senior Vice President, Treasurer, Assistant Secretary, IR Contact Officer
Age: 54
Bio & Compensation  - Reuters
E. Scott Toner Senior Vice President - Marketing
Age: 62
Bio & Compensation  - Reuters
Steven K. Burke M.D. Senior Vice President, Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
Matthew Paul Kowalsky Vice President, Legal and Secretary
Age: 44
Bio & Compensation  - Reuters
Daniel P. Gottlieb Vice President - Corporate Development
Age: 46
Bio & Compensation  - Reuters
Jonathan Leff Director
Bio & Compensation  - Reuters
Hubert Birner Ph.D. Independent Director
Age: 51
Bio & Compensation  - Reuters
Garen G. Bohlin Independent Director
Age: 69
Bio & Compensation  - Reuters